LataMed AI Corp. (OTC: LMED), a development-stage digital health and artificial intelligence technology company, announced today that it has commenced preliminary due diligence and strategic planning for its planned expansion into Colombia. The company, which focuses on telehealth infrastructure, healthcare analytics, and care coordination solutions for emerging markets, stated that the initial phase includes evaluating corporate, regulatory, legal, operational, and commercial requirements for establishing a Colombian operating subsidiary.
Management believes Colombia represents an attractive long-term market as part of its broader Latin American expansion strategy. The ongoing review process is expected to assess corporate formation, regulatory compliance, healthcare technology implementation, strategic partnerships, local operational infrastructure, and other market entry considerations necessary to support future operations.
The company noted that the evaluation builds upon its growing healthcare ecosystem by identifying opportunities to expand access to telehealth infrastructure, healthcare coordination technologies, digital healthcare services, insurance accessibility initiatives, pharmacy integration opportunities, payment accessibility solutions, and artificial intelligence-driven healthcare technologies in additional Latin American markets.
Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp., stated: "Colombia represents an important strategic opportunity as we continue executing our long-term vision of building an integrated digital healthcare ecosystem across Latin America. While we remain in the early stages of evaluating market entry requirements, we believe it is important to establish the proper legal, operational, and strategic foundation before expanding into new jurisdictions."
The company emphasized that the Colombia expansion initiative remains in the preliminary planning and due diligence stage. Management intends to complete the required corporate, regulatory, and operational review before proceeding with the establishment of a Colombian subsidiary and expects to provide additional updates as material developments occur.
For additional information, visit https://latamed.ai or review the company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
